NCT05001698View on ClinicalTrials.gov

Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

June 2, 2022

Study Completion Date

June 2, 2022

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

Anifrolumab

intravenous infusion (IV)

Trial Locations (3)

200025

Research Site, Shanghai

200040

Research Site, Shanghai

226001

Research Site, Nantong

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT05001698 - Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE) | Biotech Hunter | Biotech Hunter